Is too much neurohormonal blockade harmful?

Current Cardiology Reports

Volumn 6, Issue 3, 2004, Pages 169-175

  Anand, Inder S ^a  

^a VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUCINDOLOL; CANDESARTAN; CARVEDILOL; CATECHOLAMINE; CYTOKINE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; ETANERCEPT; INFLIXIMAB; LISINOPRIL; METOPROLOL; MOXONIDINE; NEUROHORMONE; NORADRENALIN; OMAPATRILAT; PLACEBO; RENIN; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VALSARTAN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ENDOTHELIN; HORMONE ANTAGONIST;

ADD ON THERAPY; ADRENERGIC ACTIVITY; BRADYCARDIA; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SELECTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HORMONAL REGULATION; HORMONE INHIBITION; HOSPITALIZATION; HUMAN; HYPOTENSION; LIVER DYSFUNCTION; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADRENERGIC SYSTEM; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYTOKINES; DRUG THERAPY, COMBINATION; ENDOTHELINS; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 3142671327     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0019-6     Document Type: Review

References (57)

1. Wilson JR, Schwartz JS, St. John Sutton M, et al.: Prognosis in severe heart failure and relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983, 2:403-409.
2. Szlachcic J, Massie BM, Kramer BL, et al.: Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985, 55:1037-1042.
3. Cohn JN, Levine TB, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
4. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
5. Massie BM, Conway M: Survival of patients with congestive heart failure: past, present, and future prospects. Circulation 1987, 7:IV11-IV19.
6. Anand IS, Chugh SS: Mechanisms and management of renal dysfunction in heart failure. Curr Opin Cardiol 1997, 12:251-258.
7. Anand IS: Pathogenesis of salt and water retention in the syndrome of congestive heart failure. In Heart Failure; Scientific Principles and Clinical Practice. Edited by Poole-Wilson PA, Chatterjee K, Coates AJS, et al. London: Churchill Livingstone; 1996.
8. Anand IS, Florea VG: Alterations in ventricular structure: role of left ventricular remodeling. In Heart Failure: Companion to Braunwald's Heart Disease. Edited by Mann DL. Philadelphia: Saunders; 2002.
9. Mann D, Kent R, Parsons B, Cooper C: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
10. Tan LB, Jalil JE, Pick R, et al.: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991, 69:1185-1195.
11. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
12. Anand IS, Chandrashekhar Y: Neurohormonal responses in congestive heart failure: effect of ACE inhibitors in randomized controlled clinical trials. In Heart Hypertrophy and Failure. Edited by Dhalla NS, Singhal PK, Beamish RE. Boston: Kluwer Academic Publishers; 1996:487-501.
13. Anand IS, Fisher LD, Chiang YT, et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeF. Circulation 2003, 107:1276-1281.
14. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
15. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
16. The MERIT-HF Investigators: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
17. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
18. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
19. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
20. Packer M: The ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heat Failure) Study. Preliminary data presented at the 51st annual American College of Cardiology meeting. Atlanta, GA; March 21, 2002.
21. Packer M: Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in congestive heart failure: results of the REACH-1 trial. Circulation 1998, 98(Suppl S):12.
22. Packer M, Califf RM, Konstam MA, et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002, 106:920-926.
23. The CIBIS II Investigators: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
24. Bristow MR, Gilbert EM, Abraham WT, et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996, 94:2807-2816.
25. Swedberg K, Bristow MR, Cohn JN, er al.: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002, 105:1797-1803.
26. Cohn JN, Pfeffer MA, Rouleau J, et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659-667.
27. The BEST Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667.
28. Bristow M, Krause-Steinrauf H, Abraham WT, et al.: Effect of Buchindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. Circulation 2001, 104:II-755.
29. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al.: Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000, 36:2090-2095.
30. Tang WH, Vagelos RH, Yee YG, et al.: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70-78.
31. Kawamura M, Imanashi M, Matsushima Y, et al.: Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol 1992, 19:547-553.
32. Jorde UP, Ennezat PV, Lisker J, et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000, 101:844-846.
33. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
34. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003, 362:777-781.
35. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
36. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
37. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
38. Anand IS, Glazer R, Chiang YT, et al.: A retrospective analysis of major determinants of heart failure mortality in patients receiving both ACE inhibitors and beta-blockers in Val-HeFT. J Card Fail 2003, 5:P304.
39. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
40. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854.
41. Stewart DJ, Cernacek P, Costello KB, Rouleau JL: Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992, 85:510-517.
42. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
43. Omland T, Lie RT, Aakvaag A, et al.: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994, 89:1573-1579.
44. Fukuchi M, Giaid A: Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 1998, 31(Suppl 1):S421-S423.
45. Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355.
46. Sutsch G, Kiowski W, Yan XW, et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262-2268.
47. Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106:2666-2672.
48. Wada A, Tsutamoto T, Fukai D, et al.: Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997, 30:1385-1392.
49. A Receptor Antagonist Trial in Heart Failure (EARTH . Lancet 2004, in press.
50. Mann DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999, 100:999-1008.
51. Aukrust P, Ueland T, Lien E, et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:376-382.
52. Kapadia S, Torre-Amione C, Yokoyama T, Mann DL: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 1995, 268:H517-H525.
53. Deswal A, Bozkurt B, Seta Y, et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224-3226.
54. Bozkurt B, Torre-Amione G, Warren MS, et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001, 103:1044-1047.
55. Wood S: RENEWAL trial: no improvement in CHF with etanercept. HeartWire News 2002. http://www.theheart.org
56. Mann DL, Swedberg K, Packer M, et al.: Effects of cytokine antagonism with etanercept on morbidity and mortality in patients with chronic heart failure: results of the RENAISSANCE, RECOVERY, and RENEWAL trails. Paper presented at the 6th annual meeting of the Heart Failure Society of America. Boca Raton, FL; September 25, 2002.
57. Packer M, Chung E, Batra S, et al.: Randomized placebo-controlled dose-ranging trial of infliximab, a monoclonal antibody to tumor necrosis factor-alpha, in moderate to severe heart failure. Paper presented at the annual meeting of HFSA. September 25, 2002.